Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
29 studies found for:    "nonbullous congenital ichthyosiform erythroderma" OR "Congenital Ichthyosiform Erythrodermas" OR "Congenital Ichthyosiform Erythroderma" OR "Ichthyosiform Erythroderma, Congenital" OR "Ichthyosis"
Show Display Options
Download search resultsDownload the search results for:
"nonbullous congenital ichthyosiform erythroderma" OR "Congenital Ichthyosiform Erythrodermas" OR "Congenital Ichthyosiform Erythroderma" OR "Ichthyosiform Erythroderma, Congenital" OR "Ichthyosis" (29 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Not yet recruiting A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Condition: Congenital Ichthyosis
Interventions: Drug: PAT-001, 0.1%;   Drug: PAT-001, 0.2%;   Drug: Vehicle
2 Unknown  Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous
Condition: Lamellar Ichthyosis
Intervention: Drug: apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
3 Recruiting A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
Condition: Ichthyosis
Intervention: Other: Observation
4 Completed Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis
Condition: Ichthyosis
Intervention: Drug: monolaurin cream
5 Completed Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis
Condition: Ichthyosis, Lamellar
Intervention: Drug: Liarozole
6 Enrolling by invitation Comparison of Different Concentrations of Carbamide as Moisturizers in Ichthyosis Vulgaris
Condition: Ichthyosis Vulgaris
Interventions: Other: Comparing the effect of moisturizers with 5 and 7.5 % carbamide, respectively;   Other: Comparing the effect of moisturizers with 5 and 10 % carbamide, respectively;   Other: Comparing the effect of moisturizers with 7.5 and 10 % carbamide, respectively
7 Completed
Has Results
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
Conditions: Atopic Dermatitis;   Ichthyosis Vulgaris
Intervention: Genetic: Buccal Swab
8 Withdrawn Novel Treatment for Syndromic Ichthyoses
Conditions: Syndromic Ichthyoses;   CHILD Syndrome;   Smith Lemli Opitz Syndrome;   Conradi Syndrome
Intervention: Drug: Lovastatin
9 Completed Study of Scaling Disorders and Other Inherited Skin Diseases
Conditions: Genetic Skin Disease;   Keratosis Follicularis;   Lamellar Ichthyosis
Intervention:
10 Completed A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Condition: Sjögren-Larsson Syndrome
Interventions: Drug: Active topical NS2 1% dermatologic cream;   Drug: Vehicle placebo 0.0% NS2 dermatologic cream
11 Active, not recruiting National Registry for Ichthyosis and Related Disorders
Conditions: Darier Disease;   Hailey-Hailey Disease;   Hyperkeratosis, Epidermolytic;   Ichthyosis;   Ichthyosis, Lamellar;   Ichthyosis, X-Linked;   Keratoderma
Intervention:
12 Recruiting Studies of Skin Microbes in Healthy People and in People With Skin Conditions
Conditions: Atopic Dermatitis;   Eczema;   Ichthyosis Vulgaris
Intervention:
13 Unknown  Xeroderma Pigmentosum Patient Experiences
Condition: Xeroderma Pigmentosum
Intervention: Other: Survey Study
14 Recruiting International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases
Condition: Neutral Lipid Storage Disease
Intervention:
15 Recruiting Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M
Conditions: Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV);   Neutral Lipid Storage Disease With Myopathy (NLSD-M)
Intervention: Dietary Supplement: CNT-02
16 Completed The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM)
Condition: Neutral Lipid Storage Disease
Intervention: Drug: Fibrate treatment
17 Unknown  Use of Fish Skin Extracellular Matrix (ECM) to Facilitate Chronic Wound Healing
Conditions: Pressure Ulcers;   Venous Ulcers;   Diabetic Ulcers;   Chronic Ulcer of Foot;   Trauma-related Wound
Intervention: Device: Marigen Wound Dressing
18 Recruiting Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy
Conditions: Metabolism, Inborn Errors;   Lipid Metabolism, Inborn Errors;   Carbohydrate Metabolism, Inborn Errors;   Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogenin-1 Deficiency (Glycogen Storage Disease Type XV);   Carnitine Palmitoyl Transferase 2 Deficiency;   VLCAD Deficiency;   Medium-chain Acyl-CoA Dehydrogenase Deficiency;   Multiple Acyl-CoA Dehydrogenase Deficiency;   Carnitine Transporter Deficiency;   Neutral Lipid Storage Disease;   Glycogen Storage Disease Type II;   Glycogen Storage Disease Type III;   Glycogen Storage Disease Type IV;   Glycogen Storage Disease Type V;   Muscle Phosphofructokinase Deficiency;   Phosphoglucomutase 1 Deficiency;   Phosphoglycerate Mutase Deficiency;   Phosphoglycerate Kinase Deficiency;   Phosphorylase Kinase Deficiency;   Beta Enolase Deficiency;   Lactate Dehydrogenase Deficiency;   Glycogen Synthase Deficiency
Intervention: Other: Sugar
19 Active, not recruiting Clinical Trial Using Humira in Netherton Syndrome
Condition: Netherton Syndrome
Intervention: Drug: Adalimumab
20 Recruiting Natural History and Biological Study of Netherton Syndrome
Conditions: Netherton Syndrome;   Healthy
Interventions: Other: Biopsy;   Other: Blood sample

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.